Clinical Trials Logo
  1. Home
  2. Retinal Dystrophies
  3. NCT03853252

iPS Cells of Patients for Models of Retinal Dystrophies — RETIPS  

Retinal Dystrophies Clinical Trial

Official title:
iPS Cells of Patients for Models of Retinal Dystrophies

Clinical Trial Summary

The investigators are focused on inherited retinal dystrophies with an aim to further understand disease pathophysiology and to elaborate novel treatments, as, to date, there is no effective treatment to prevent blindness. The main goal of this study is to generate human cellular models of healthy and disease retinas and perform studies to evaluate the efficiency of gene therapy approaches for different diseases. Skin biopsies of volunteers are cultured to isolate fibroblasts that are then reprogrammed into iPS cells. Healthy and disease-specific iPS cells are then differentiated into retinal models. This study should help to elucidate disease pathways and to provide proof-of-concept for various therapeutic approaches.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03853252
Study type Interventional
Source University Hospital, Montpellier
Contact Vasiliki Kalatzis, PhD
Phone (0)499636097
Email vasiliki.kalatzis@inserm.fr
Status Recruiting
Phase N/A
Start date November 3, 2014
Completion date November 2024
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04123626 - A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene Phase 1/Phase 2
Completed NCT01546181 - Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases
Recruiting NCT03592017 - Performance of Long-wavelength Autofluorescence Imaging N/A
Recruiting NCT04855045 - An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene. Phase 2/Phase 3
Recruiting NCT06177977 - SS-HH-OCT as a Novel Diagnostic Modality for Early-Onset Retinal Dystrophies (EORDs) N/A
Completed NCT02983305 - Optical Head-Mounted Display Technology for Low Vision Rehabilitation N/A
Not yet recruiting NCT06455826 - MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby) Phase 1
Recruiting NCT05573984 - Natural History of PRPF31 Mutation-Associated Retinal Dystrophy
Completed NCT03763227 - Intravitreal Ranibizumab (Lucentis®) in the Treatment of Non-leaking Macular Cysts in Retinal Dystrophy Phase 2
Completed NCT04945772 - Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE] Phase 2
Recruiting NCT05218928 - Qualification for Cone-Optogenetics
Recruiting NCT05294978 - EyeConic: Qualification for Cone-Optogenetics
Completed NCT03843840 - Dual Wavelength OCT
Enrolling by invitation NCT06162585 - Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study
Recruiting NCT02014389 - Evaluation of Objective Perimetry Using Chromatic Multifocal Pupillometer
Not yet recruiting NCT06319872 - The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration Phase 1